HUMA Live signals | Maximize Profits with Getagraph.com

SELL 110812 min ago

@ $3.93

Issued: 14 Feb 2024 @ 09:30

Return: -0.25%

Previous signal: Feb 13 - 12:18

Previous signal: Buy

Return: 2.88 %

Live Chart Being Loaded With Signals

Commentary (30 Apr 2024 @ 16:00):

Stats
Today's Volume	936 459
Average Volume	1.38M
Market Cap	466.81M
EPS	$0 ( 2024-03-22 )
Next earnings date	( $-0.230 ) 2024-05-10
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-3.66
ATR14	$0.00700 (0.18%)

Insider Trading

Date	Person	Action	Amount	type
2023-12-08	Scheessele William John	Buy	276 000	Stock Options (right to buy)
2023-12-08	Prichard Heather Ledbetter	Buy	290 000	Stock Options (right to buy)
2023-12-11	Prichard Heather Ledbetter	Buy	525	Stock Options (right to buy)
2023-12-08	Parikh Shamik J	Buy	283 000	Stock Options (right to buy)
2023-12-08	Cao Yang	Buy	210 000	Stock Options (right to buy)

INSIDER POWER
-74.07
Last 98 transactions
Buy: 5 335 317 \| Sell: 41 328 241

Volume Correlation

Long: 0.21 (neutral)

Short: 0.68 (moderate)

Signal:(36.917) Neutral

Humacyte, Inc. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Humacyte, Inc. Correlation - Currency/Commodity

0.22
( neutral )

0.12
( neutral )

0.00
( neutral )

0.51
( weak )

Humacyte, Inc. Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-7.72M (0.00 %)
EPS:	$-1.070

FY	2023
Revenue:	$0
Gross Profit:	$-7.72M (0.00 %)
EPS:	$-1.070

FY	2022
Revenue:	$1.57M
Gross Profit:	$-6.69M (-427.48 %)
EPS:	$0.620

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$0

Financial Reports:

No articles found.

Humacyte, Inc.

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. The company is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; and coronary artery bypass grafting, as well as developing its HAVs for pediatric heart surgery and cellular therapy delivery, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.